|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cuzick J, Thorat MA, Andriole G, Brawley
OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et
al: Prevention and early detection of prostate cancer. Lancet
Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abdollah F, Sun M, Schmitges J, Thuret R,
Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi
F and Karakiewicz PI: Survival benefit of radical prostatectomy in
patients with localized prostate cancer: Estimations of the number
needed to treat according to tumor and patient characteristics. J
Urol. 188:73–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molitierno J, Evans A, Mohler JL, Wallen
E, Moore D and Pruthi RS: Characterization of biochemical
recurrence after radical prostatectomy. Urol Int. 77:130–134. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shariat SF, Karakiewicz PI, Roehrborn CG
and Kattan MW: An updated catalog of prostate cancer predictive
tools. Cancer. 113:3075–3099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stephenson AJ, Scardino PT, Eastham JA,
Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA and Kattan
MW: Postoperative nomogram predicting the 10-year probability of
prostate cancer recurrence after radical prostatectomy. J Clin
Oncol. 23:7005–7012. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lilja H, Ulmert D and Vickers AJ:
Prostate-specific antigen and prostate cancer: Prediction,
detection and monitoring. Nat Rev Cancer. 8:268–278. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Velonas VM, Woo HH, dos Remedios CG and
Assinder SJ: Current status of biomarkers for prostate cancer. Int
J Mol Sci. 14:11034–11060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, McKeehan WL, Wang F and Xie R:
MAP1S enhances autophagy to suppress tumorigenesis. Autophagy.
8:278–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang X, Zhong W, Huang H, He H, Jiang F,
Chen Y, Yue F, Zou J, Li X, He Y, et al: Autophagy defects
suggested by low levels of autophagy activator MAP1S and high
levels of autophagy inhibitor LRPPRC predict poor prognosis of
prostate cancer patients. Mol Carcinog. 54:1194–1204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Smith JS, Tachibana I, Pohl U, Lee HK,
Thanarajasingam U, Portier BP, Ueki K, Ramaswamy S, Billings SJ,
Mohrenweiser HW, et al: A transcript map of the chromosome 19q-arm
glioma tumor suppressor region. Genomics. 64:44–50. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang P, Kollmeyer TM, Buckner K, Bamlet W,
Ballman KV and Jenkins RB: Polymorphisms in GLTSCR1 and ERCC2 are
associated with the development of oligodendrogliomas. Cancer.
103:2363–2372. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Neville PJ, Conti DV, Krumroy LM, Catalona
WJ, Suarez BK, Witte JS and Casey G: Prostate cancer aggressiveness
locus on chromosome segment 19q12-q13.1 identified by linkage and
allelic imbalance studies. Genes Chromosomes Cancer. 36:332–339.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Slager SL, Schaid DJ, Cunningham JM,
McDonnell SK, Marks AF, Peterson BJ, Hebbring SJ, Anderson S,
French AJ and Thibodeau SN: Confirmation of linkage of prostate
cancer aggressiveness with chromosome 19q. Am J Hum Genet.
72:759–762. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Epstein JI, Feng Z, Trock BJ and
Pierorazio PM: Upgrading and downgrading of prostate cancer from
biopsy to radical prostatectomy: Incidence and predictive factors
using the modified Gleason grading system and factoring in tertiary
grades. Eur Urol. 61:1019–1024. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Partin AW, Kattan MW, Subong EN, Walsh PC,
Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of
prostate-specific antigen, clinical stage, and gleason score to
predict pathological stage of localized prostate cancer. A
multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie ZC, Li TT, Gan BL, Gao X, Gao L, Chen
G and Hu XH: Investigation of miR-136-5p key target genes and
pathways in lung squamous cell cancer based on TCGA database and
bioinformatics analysis. Pathol Res Pract. 214:644–654. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo Z, Chen X, Du T, Zhu D, Lai Y, Dong W,
Wu W, Lin C, Liu L and Huang H: Elevated levels of epithelial cell
transforming sequence 2 predicts poor prognosis for prostate
cancer. Med Oncol. 34:132017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang KX, Firus J, Prieur B, Jia W and
Rennie PS: To die or to survive, a fatal question for the destiny
of prostate cancer cells after androgen deprivation therapy.
Cancers (Basel). 3:1498–1512. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rahman S, Sowa ME, Ottinger M, Smith JA,
Shi Y, Harper JW and Howley PM: The Brd4 extraterminal domain
confers transcription activation independent of pTEFb by recruiting
multiple proteins, including NSD3. Mol Cell Biol. 31:2641–2652.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adam K, Lambert M, Lestang E, Champenois
G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y
and Mayeux P: Control of Pim2 kinase stability and expression in
transformed human haematopoietic cells. Biosci Rep. 35:e002742015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu J, Zhang T, Wang T, You L and Zhao Y:
PIM kinases: An overview in tumors and recent advances in
pancreatic cancer. Future Oncol. 10:865–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu Z, Zhao X, Huang L, Zhang T, Yang F,
Xie L, Song S, Miao P, Zhao L, Sun X, et al: Proviral insertion in
murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase
M2 (PKM2) and promotes glycolysis in cancer cells. J Biol Chem.
288:35406–35416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren K, Gou X, Xiao M, Wang M, Liu C, Tang
Z and He W: The over-expression of Pim-2 promote the tumorigenesis
of prostatic carcinoma through phosphorylating eIF4B. Prostate.
73:1462–1469. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bohensky J, Shapiro IM, Leshinsky S,
Watanabe H and Srinivas V: PIM-2 is an independent regulator of
chondrocyte survival and autophagy in the epiphyseal growth plate.
J Cell Physiol. 213:246–251. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amaravadi R, Kimmelman AC and White E:
Recent insights into the function of autophagy in cancer. Genes
Dev. 30:1913–1930. 2016. View Article : Google Scholar : PubMed/NCBI
|
